Usual ACE Inhibitor Therapy in CKD Patients Is Associated with Lower Plasma Aldosterone Levels than Usual Angiotensin Receptor Blocker Therapy

Kidney and Blood Pressure Research - Tập 30 Số 5 - Trang 299-305 - 2007
Nabil F. Haddad1, James Rajan1, Haikady N. Nagaraja2, Anil Agarwal1, Lee A. Hebert1
1Internal Medicine, and
2Statistics, The Ohio State University, Columbus, Ohio, USA

Tóm tắt

<i>Background:</i> Attenuating aldosterone (ALDO) effects may be important in slowing kidney and cardiovascular disease progression. This study tested whether ACE inhibitor (I) therapy achieves lower plasma (p) ALDO levels than angiotensin receptor blocker (ARB) therapy when they are used under usual clinical conditions in chronic kidney disease (CKD) patients. <i>Methods:</i> Consecutive CKD patients (n = 123) were studied. They were clinically stable and receiving either ACEI (n = 77) or ARB (n = 46) (physician’s choice) for ≧3 months. <i>Results:</i> Mean pALDO in the ACEI cohort was 7.8 ± 5.7 (SD) ng/dl compared to 12.3 ± 9.8 ng/dl in the ARB cohort (p = 0.0018, normal ambulatory pALDO 9.4–33.8 ng/dl). The pALDO difference was not explained by differences in age, sex, race, body weight, diagnosis of diabetes; the use of β-blockers, calcium channel blockers or diuretic; systolic or diastolic blood pressure; plasma renin, serum creatinine, sodium, potassium, or bicarbonate levels; 24-hour urine potassium, sodium, urea or protein excretion; or ACEI or ARB dose. <i>Conclusions:</i> Mean pALDO is about 60% higher with ARB therapy than ACEI therapy when these drugs are customarily used in CKD patients. This difference could be clinically important with regard to kidney and cardiovascular protection.

Từ khóa


Tài liệu tham khảo

10.1136%2Fhrt.2003.025312

10.1097%2F01.hco.0000129667.34622.14

10.1056%2FNEJMp048132

10.1016%2Fj.amjhyper.2004.12.005

10.1016%2Fj.jacc.2005.01.014

10.1097%2F01.ASN.0000100145.27188.33

10.1007%2Fs11906-004-0029-1

10.1111%2Fj.1523-1755.2004.00701.x

10.1210%2Fjc.83.10.3517

10.1016%2FS0021-9150%2802%2900363-5

10.1097%2F01.ASN.0000083982.74108.54

10.1161%2F01.HYP.0000176236.55322.18

10.1161%2F01.HYP.0000123572.45556.a5

10.1681%2FASN.2005040390

10.1161%2F01.HYP.0000161990.98383.ad

10.1111%2Fj.1523-1755.2005.00263.x

10.1681%2FASN.2005020129

10.1681%2FASN.2005111196

10.1097%2F01.hjh.0000170379.08214.5a

10.1111%2Fj.1523-1755.2004.00524.x

10.1097%2F01.ASN.0000132473.50966.14

10.1111%2Fj.1523-1755.2000.00381.x

10.1111%2Fj.1523-1755.2004.00857.x

10.1007%2Fs00125-004-1542-0

10.1056%2FNEJMoa042274

10.1097%2F01.ASN.0000118342.72706.69

10.1007%2FBF01059447

10.1161%2FCIRCULATIONAHA.105.594986

10.1161%2FCIRCULATIONAHA.105.594978

10.1016%2FS0140-6736%2803%2912229-5

10.1016%2FS0735-1097%2802%2901689-3

10.1097%2F01.ASN.0000131528.00773.A9

10.1097%2F01.ASN.0000133013.36628.87

10.1161%2F01.CIR.0000163562.82134.8E

10.1210%2Fen.2004-1057

Thông tin
Thông tin xuất bản

Kidney and Blood Pressure Research

Tập 30 Số 5

299-305

Thông tin tác giả